TJP1 and ischemic stroke: CircDLGAP4 levels were significantly decreased in the plasma of acute ischemic stroke patients and a mouse model of ischemic stroke, and upregulation of circDLGAP4 expression significantly inhibited miR-143 activity and resulting in improved neurological deficits, decreased infarct areas, and attenuated blood–brain barrier extravasation along with ameliorated the downregulation of tight junction proteins, including claudin-5, occludin, and ZO-1 in the preclinical ischemic stroke models [63].